Identification
- Generic Name
- Topsalysin
- DrugBank Accession Number
- DB05160
- Background
Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Topsalysin
- External IDs
- PRX-302
- PRX302
Pharmacology
- Indication
Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
PRX302 is a targeted pro-drug that turns into a potent anti-cancer agent once activated by the enzyme, prostate specific antigen (PSA), produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX302 destroys the cells by punching holes in the cell membrane.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LSA9D0A43Q
- CAS number
- 917121-25-6
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347909989
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Benign Prostatic Hyperplasia (BPH) 1 2 Completed Treatment Benign Prostatic Hyperplasia (BPH) 1 2 Completed Treatment Locally Recurrent Prostate Cancer 1 2 Completed Treatment Prostate Cancer 2 1 Completed Treatment Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51